Human papillomavirus vaccination in low-resource countries: Lack of evidence to support vaccinating sexually active women

British Journal of Cancer

Volumn 107, Issue 9, 2012, Pages 1445-1450

  Tsu, V ^a   Murray, M ^a   Franceschi, S ^b  

^a PATH   (United States)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

cervical cancer; developing countries; HPV vaccination; target population

Indexed keywords

STEROID HORMONE; WART VIRUS VACCINE;

ADOLESCENT; ADULT; CANCER SCREENING; CARCINOGENESIS; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG EFFICACY; EVIDENCE BASED PRACTICE; FEMALE; HEALTH CARE ORGANIZATION; HUMAN; INNATE IMMUNITY; INTENTION TO TREAT ANALYSIS; LOWEST INCOME GROUP; MEDLINE; PAPILLOMAVIRUS INFECTION; PREVENTIVE MEDICINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL BEHAVIOR; SYSTEMATIC REVIEW; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION;

ADOLESCENT; ADULT; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SEXUAL BEHAVIOR; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84867897931     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.404     Document Type: Review

References (45)

1. Adams M, Jasani B, Fiander A (2009) Prophylactic HPV vaccination for women over 18 years of age. Vaccine 27(25-26): 3391-3394
2. Basu P, Ngan HY, Hseon TE (2009) HPV vaccination in women over 25 years of age: Asian Cervical Cancer Prevention Advisory Board recommendations. J Obstet Gynaecol Res 35: 712-716
3. Castellsague X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, Luna J, Myers E, Mallary S, Bautista OM, Bryan J, Vuocolo S, Haupt RM, Saah A (2011) End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 105: 28-37
4. Castellsague X, Schneider A, Kaufmann AM, Bosch FX (2009) HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol 115(3 Suppl): S15-S23
5. Castle PE, Fetterman B, Akhtar I, Husain M, Gold MA, Guido R, Glass AG, Kinney W (2009) Age-appropriate use of human papillomavirus vaccines in the U.S. Gynecol Oncol 114(2): 365-369
6. Chesson H (2010) Cost-effectiveness of quadrivalent HPV vaccination of adult women. Available at http://www.oralcancerfoundation.org/hpv/pdf/02-4-hpv. pdf
7. Dasbach EJ, Insinga RP, Elbasha EH (2008a) The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 115(8): 947-956
8. Dasbach EJ, Largeron N, Elbasha EH (2008b) Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model. Expert Rev Pharmacoecon Outcomes Res 8(5): 491-500
9. Elbasha EH, Dasbach EJ, Insinga RP (2007) Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 13(1): 28-41
10. Elbasha EH, Dasbach EJ, Insinga RP, Haupt RM, Barr E (2009) Age-based programs for vaccination against HPV. Value Health 12(5): 697-707
11. Elit L, Jimenez W, McAlpine J, Ghatage P, Miller D, Plante M (2011) SOGCGOC-SCC Joint Policy Statement. No. 255, March 2011. Cervical cancer prevention in low-resource settings. J Obstet Gynaecol Can 33(3): 272-279
12. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Globocan 2008 V1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. International Agency for Research on Cancer: Lyon, France, Available at http://globocan.iarc.fr
13. Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, Bosch FX, Ferreccio C, Hieu NT, Lazcano-Ponce E, Matos E, Molano M, Qiao YL, Rajkumar R, Ronco G, de SS, Shin HR, Sukvirach S, Thomas JO, Meijer CJ, Munoz N (2006) Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 119: 2677-2684
14. Garland SM, Smith JS (2010) Human papillomavirus vaccines current status and future prospects. Drugs 70(9): 1079-1098
15. GAVI Alliance (2011) GAVI takes first steps to introduce vaccines against cervical cancer and rubella. GAVI Alliance. Available at http://www. gavialliance.org/library/news/press-releases/2011/gavi-takes-first-steps- tointroduce-vaccines-against-cervical-cancer-and-rubella/
16. Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY (2008) Health and economic outcomes of HPV 16, 18 vaccination in 72 GAVI-eligible countries. Vaccine 26: 4080-4093
17. Grant LA, Dunne EF, Chesson H, Markowitz LE (2011) Considerations for human papillomavirus (HPV) vaccination of mid-adult women in the United States. Vaccine 29: 2365-2370
18. Hildesheim A, Herrero R (2007) Human papillomavirus vaccine should be given before sexual debut for maximum benefit. J Infect Dis 196(10): 1431-1432
19. Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Reynales-Shigematsu LM (2007) Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 26(1): 128-139
20. Jit M, Choi YH, Edmunds WJ (2008) Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 337: a769
21. Kim JJ, Goldie SJ (2008) Health and economic implications of HPV vaccination in the United States. N Engl J Med 359: 821-832
22. Kim JJ, Ortendahl J, Goldie SJ (2009) Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med 151: 538-545
23. Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, Roder D, Ross J, Wain G (2007) A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health 4(3): 165-175
24. Lu B, Kumar A, Castellsague X, Giuliano AR (2011) Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis 11: 13
25. Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER (2009) Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis 200(7): 1059-1067
26. Monsonego J, Cortes J, Greppe C, Hampl M, Joura E, Singer A (2010) Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine. Vaccine 28(51): 8065-8072
27. Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Munoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Maansson R, Vuocolo S, Hesley TM, Saah A, Barr E, Haupt RM (2009) Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 5: 696-704
28. Paavonen J (2010) At what age should we be vaccinating for human papillomavirus? Gynecol Obstet Invest 70(4): 233-236
29. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, Greenacre M (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374: 301-314
30. Pedersen C, Petaja T, Strauss G, Rurnke HC, Poder A, Richardus JH, Spiessens B, Descamps D, Hardt K, Lehtinen M, Dubin G (2007) Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant J Adolesc Health 40: 564-571
31. Plummer M, Peto J, Franceschi S (2011) Time since first sexual intercourse and the risk of cervical cancer. Int J Cancer 130(11): 2638-2644
32. Poppe WA, Simon PH, De Ridder MR (2010) Why consider human papillomavirus vaccination in older women? Gynecol Obstet Invest 70(4): 237-243
33. Prymula R, Anca I, André F, Bakir M, Czajka H, Lutsar I, Mészner Z, Salman N, Simurka P, Usonis V (2009) Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for the introduction of HPV vaccines. Eur J Pediatr 168(9): 1031-1035
34. Roberts JN (2011) Clinical Review of Biologics License Application Supplement STN# 125126/773-mid-adult women indication for Gardasil. Food and Drug Administration. Available at http://www.fda.gov/BiologicsBloodVaccines/ Vaccines/ApprovedProducts/ucm094042.htm
35. Rodriguez AC, Schiffman M, Herrero R, Hildesheim A, Bratti C, Sherman ME, Solomon D, Guillen D, Alfaro M, Morales J, Hutchinson M, Katki H, Cheung L, Wacholder S, Burk RD (2010) Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 102: 315-324
36. Singh S, Wulf D, Samara R, Cuca YP (2000) Gender differences in the timing of first intercourse: data from 14 countries. Int Fam Plan Perspect 26: 21-28
37. Solomon D, Castle P, Hildesheim A, Katki HA, Schiffman M, Wacholder S (2009) HPV vaccination in women aged 24-45 years. Lancet 374(9697): 1239-1240
38. Stanley M (2010) Prophylactic human papillomavirus vaccines: will they do their job? J Intern Med 267(3): 251-259
39. Suarez E, Smith JS, Bosch FX, Nieminen P, Chen CJ, Torvinen S, Demarteau N, Standaert B (2008) Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine 26(Suppl 5): F29-F45
40. Szarewski A, Poppe WA, Skinner SR, Wheeler CM, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Hedrick J, Jaisamrarn U, Limson G, Garland S, Romanowski B, Aoki FY, Schwarz TF, Bosch FX, Harper DM, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G (2011) Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer 131(1): 106-116
41. The FUTURE II Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356: 1915-1927
42. Usher C, Tilson L, Olsen J, Jepsen M, Walsh C, Barry M (2008) Costeffectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model. Vaccine 26: 5654-5661
43. Westra TA, Rozenbaum MH, Rogoza RM, Nijman HW, Daemen T, Postma MJ, Wilschut JC (2011) Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses. J Infect Dis 204(3): 377-384
44. World Health Organization (2009) Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec 84: 118-131
45. Wright Jr. TC, Huh WK, Monk BJ, Smith JS, Ault K, Herzog TJ (2008) Age considerations when vaccinating against HPV. Gynecol Oncol 109(2 Suppl): S40-S47